Bio-Path Holdings Inc (NASDAQ:BPTH), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last few months.

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination ...

Bio-Path says the first patient treated with a higher dose in Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. Bio-Path reports its second-quarter financial results last ...

A downtrend has been apparent in Bio-Path (BPTH) lately. While the stock has lost 8.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading ...

About Bio-Path Holdings Inc. Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its ...

The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...